{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:58:18Z","timestamp":1794020298893,"version":"4.8.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.lanepe.2023.100797","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:04:10Z","timestamp":1706745850000},"page":"100797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["Atrial fibrillation: stroke prevention"],"prefix":"10.1016","volume":"37","author":[{"given":"Tze-Fan","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana S.","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacasi.2022.05.005","article-title":"Stroke prevention in atrial fibrillation: a scientific statement of JACC: Asia (Part 1)","volume":"2","author":"Chiang","year":"2022","journal-title":"JACC Asia"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacasi.2022.06.004","article-title":"Stroke prevention in atrial fibrillation: a scientific statement of JACC: Asia (Part 2)","volume":"2","author":"Chiang","year":"2022","journal-title":"JACC Asia"},{"issue":"Suppl O","key":"10.1016\/j.lanepe.2023.100797_bib3","doi-asserted-by":"crossref","first-page":"O14","DOI":"10.1093\/eurheartj\/suaa178","article-title":"Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal","volume":"22","author":"Lane","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.lanepe.2023.100797_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111482","article-title":"Relationship between multimorbidity and outcomes in atrial fibrillation","volume":"153","author":"Proietti","year":"2021","journal-title":"Exp Gerontol"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100797_bib5","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.mayocp.2019.06.012","article-title":"Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use","volume":"94","author":"Proietti","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.lanepe.2023.100797_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101652","article-title":"Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients","volume":"79","author":"Proietti","year":"2022","journal-title":"Ageing Res Rev"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100797_bib7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 Focused update consensus guidelines of the Asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemostasis"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100797_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0040-1716408","article-title":"The 4S-AF scheme (stroke risk; symptoms; severity of burden; substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation","volume":"121","author":"Potpara","year":"2021","journal-title":"Thromb Haemostasis"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib11","first-page":"31","article-title":"2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening","volume":"38","author":"Chan","year":"2022","journal-title":"J\u00a0Arrhythm"},{"issue":"20","key":"10.1016\/j.lanepe.2023.100797_bib12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.lanepe.2023.100797_bib13","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.08.019","article-title":"Mobile photoplethysmographic technology to detect atrial fibrillation","volume":"74","author":"Guo","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.lanepe.2023.100797_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/CIRCULATIONAHA.122.060291","article-title":"Detection of atrial fibrillation in a large population using wearable devices: the Fitbit heart study","volume":"146","author":"Lubitz","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/europace\/euac038","article-title":"How to use digital devices to detect and manage arrhythmias: an EHRA practical guide","volume":"24","author":"Svennberg","year":"2022","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100797_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cvdhj.2022.03.003","article-title":"Usability of a smartwatch for atrial fibrillation detection in older adults after stroke","volume":"3","author":"Ding","year":"2022","journal-title":"Cardiovasc Digit Health J"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cvdhj.2023.04.002","article-title":"Anxiety, patient activation, and quality of life among stroke survivors prescribed smartwatches for atrial fibrillation monitoring","volume":"4","author":"Paul","year":"2023","journal-title":"Cardiovasc Digit Health J"},{"issue":"26","key":"10.1016\/j.lanepe.2023.100797_bib18","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/europace\/euab280","article-title":"Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry","volume":"24","author":"Ding","year":"2022","journal-title":"Europace"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13825","article-title":"Clinical utility and prognostic implications of the 4S-AF scheme: report from Asia pacific heart rhythm society atrial fibrillation registry","volume":"52","author":"Chao","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib21","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s11739-021-02890-x","article-title":"Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort","volume":"17","author":"Malavasi","year":"2022","journal-title":"Intern Emerg Med"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100797_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/europace\/euab202","article-title":"Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF long-term general registry","volume":"24","author":"Rivera-Caravaca","year":"2022","journal-title":"Europace"},{"issue":"20","key":"10.1016\/j.lanepe.2023.100797_bib23","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.119.041303","article-title":"Stroke risk as a function of atrial fibrillation duration and CHA(2)DS(2)-VASc score","volume":"140","author":"Kaplan","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ahj.2012.10.010","article-title":"Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: the Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study","volume":"165","author":"Turakhia","year":"2013","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.lanepe.2023.100797_bib25","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jacc.2018.07.077","article-title":"Provider specialty, anticoagulation, and stroke risk in patients with atrial fibrillation and cancer","volume":"72","author":"O'Neal","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.lanepe.2023.100797_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejim.2023.03.001","article-title":"Clinical outcomes of patients with incident atrial fibrillation diagnosed by cardiologists compared to non-cardiologists","volume":"112","author":"Liu","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"21","key":"10.1016\/j.lanepe.2023.100797_bib27","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1093\/eurheartj\/ehs071","article-title":"Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation","volume":"33","author":"Hendriks","year":"2012","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/europace\/euab092","article-title":"The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review","volume":"23","author":"Stevens","year":"2021","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100797_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/a-1515-9630","article-title":"Adherence to the 'atrial fibrillation better care' pathway in patients with atrial fibrillation: impact on clinical outcomes-A systematic review and meta-analysis of 285,000 patients","volume":"122","author":"Romiti","year":"2022","journal-title":"Thromb Haemostasis"},{"issue":"13","key":"10.1016\/j.lanepe.2023.100797_bib30","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jacc.2020.01.052","article-title":"Mobile health technology to improve care for patients with atrial fibrillation","volume":"75","author":"Guo","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"31","key":"10.1016\/j.lanepe.2023.100797_bib31","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/eurheartj\/ehac265","article-title":"A\u00a0multinational European network to implement integrated care in elderly multimorbid atrial fibrillation patients: the AFFIRMO Consortium","volume":"43","author":"Johnsen","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/FJC.0000000000000750","article-title":"Should we judge stroke risk by static or dynamic risk scores? A focus on the dynamic nature of stroke and bleeding risks in patients with atrial fibrillation","volume":"74","author":"Domek","year":"2019","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.lanepe.2023.100797_bib33","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1055\/s-0039-1683933","article-title":"Incident Co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially 'low-risk' patients","volume":"119","author":"Chao","year":"2019","journal-title":"Thromb Haemostasis"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100797_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/a-1467-2993","article-title":"Improving stroke risk prediction in the general population: a comparative assessment of common clinical rules, a new multimorbid index, and machine-learning-based algorithms","volume":"122","author":"Lip","year":"2022","journal-title":"Thromb Haemostasis"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib36","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/ehjqcco\/qcab037","article-title":"Improving dynamic stroke risk prediction in non-anticoagulated patients with and without atrial fibrillation: comparing common clinical risk scores and machine learning algorithms","volume":"8","author":"Lip","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100797_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA(2)DS(2)-VA score rather than CHA(2)DS(2)-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.lanepe.2023.100797_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e3522","article-title":"Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study","volume":"344","author":"Friberg","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2023.100797_bib39","doi-asserted-by":"crossref","first-page":"h7013","DOI":"10.1136\/bmj.h7013","article-title":"Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies","volume":"532","author":"Emdin","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100797_bib40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/STROKEAHA.116.015900","article-title":"Do women with atrial fibrillation experience more severe strokes? Results from the Austrian stroke unit registry","volume":"48","author":"Lang","year":"2017","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.lanepe.2023.100797_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/1060028020904969","article-title":"The tasmanian atrial fibrillation study (TAFS): differences in stroke prevention according to sex","volume":"54","author":"Pilcher","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100797_bib42","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1253\/circj.CJ-15-0095","article-title":"Validation of risk scoring system excluding female sex from CHA2DS2-VASc in Japanese patients with nonvalvular atrial fibrillation\u2013subanalysis of the J-RHYTHM registry","volume":"79","author":"Tomita","year":"2015","journal-title":"Circ J"},{"issue":"7","key":"10.1016\/j.lanepe.2023.100797_bib43","first-page":"1823","article-title":"Validation of the CHA2DS2-VA score (excluding female sex) in nonvalvular atrial fibrillation patients: a nationwide population-based study","volume":"11","author":"Choi","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"7","key":"10.1016\/j.lanepe.2023.100797_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.lanepe.2023.100797_bib45","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/STROKEAHA.116.013253","article-title":"Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor Be anticoagulated?","volume":"47","author":"Fauchier","year":"2016","journal-title":"Stroke"},{"issue":"14","key":"10.1016\/j.lanepe.2023.100797_bib46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jacc.2015.01.044","article-title":"Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score","volume":"65","author":"Lip","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib47","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jacc.2015.05.044","article-title":"Net clinical benefit for oral anticoagulation, aspirin, or No therapy in nonvalvular atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex)","volume":"66","author":"Lip","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100797_bib48","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.lanepe.2023.100797_bib49","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehy837","article-title":"Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities","volume":"40","author":"Chao","year":"2019","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.lanepe.2023.100797_bib50","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J\u00a0Thromb Haemostasis"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib51","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and asia-pacific expert consensus paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemostasis"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100797_bib52","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"Borre","year":"2018","journal-title":"Thromb Haemostasis"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib53","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.amjmed.2020.03.019","article-title":"Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial","volume":"133","author":"Guo","year":"2020","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00392-021-01816-z","article-title":"Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation","volume":"111","author":"Chao","year":"2022","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib55","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb Haemostasis"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.hrthm.2015.08.017","article-title":"Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians?","volume":"13","author":"Chao","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.lanepe.2023.100797_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.11.025","article-title":"Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study","volume":"254","author":"Chao","year":"2018","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib58","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/ehjqcco\/qcab050","article-title":"Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study","volume":"8","author":"Chao","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100797_bib59","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"14","key":"10.1016\/j.lanepe.2023.100797_bib60","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/CIRCULATIONAHA.118.036046","article-title":"Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in taiwan","volume":"138","author":"Chao","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib61","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mayocp.2020.08.042","article-title":"Non-vitamin K antagonist oral anticoagulants in elderly (>\/=85 years) patients with newly diagnosed atrial fibrillation: changing clinical practice and outcomes for stroke prevention in a nationwide cohort study","volume":"96","author":"Cheng","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"9921","key":"10.1016\/j.lanepe.2023.100797_bib62","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib63","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.lanepe.2023.100797_bib64","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib65","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.chest.2019.11.025","article-title":"Comparing the effectiveness and safety of nonvitamin K antagonist oral anticoagulants and warfarin in elderly asian patients with atrial fibrillation: a nationwide cohort study","volume":"157","author":"Chao","year":"2020","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad120","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study","volume":"25","author":"Liu","year":"2023","journal-title":"Europace"},{"issue":"13","key":"10.1016\/j.lanepe.2023.100797_bib67","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100797_bib68","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.lanepe.2023.100797_bib69","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.lanepe.2023.100797_bib70","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Chan","year":"2020","journal-title":"Heart Rhythm"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib71","article-title":"Prescribing patterns and outcomes of edoxaban in atrial fibrillation: one-year data from the global ETNA-AF program","volume":"12","author":"Chao","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100797_bib72","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/heartjnl-2022-321114","article-title":"Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"109","author":"Caso","year":"2023","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib73","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/jnnp-2021-328391","article-title":"Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation","volume":"93","author":"Polymeris","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100797_bib74","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1161\/STROKEAHA.121.038239","article-title":"Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the RENO-EXTEND study","volume":"53","author":"Paciaroni","year":"2022","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib75","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/01.STR.30.4.834","article-title":"Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications","volume":"30","author":"Blackshear","year":"1999","journal-title":"Stroke"},{"issue":"24","key":"10.1016\/j.lanepe.2023.100797_bib76","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.lanepe.2023.100797_bib77","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis","volume":"65","author":"Holmes","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2021.10.023","article-title":"4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation","volume":"79","author":"Osmancik","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.lanepe.2023.100797_bib79","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib80","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.acvd.2011.11.005","article-title":"Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials","volume":"105","author":"Caldeira","year":"2012","journal-title":"Archives of cardiovascular diseases"},{"issue":"14","key":"10.1016\/j.lanepe.2023.100797_bib81","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1474-4422(22)00436-7","article-title":"Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial","volume":"22","author":"Jensen","year":"2023","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib83","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.7326\/M21-4798","article-title":"Early rhythm control therapy for atrial fibrillation in low-risk patients: a nationwide propensity score-weighted study","volume":"175","author":"Kim","year":"2022","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100797_bib84","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1055\/a-1807-0336","article-title":"Early rhythm control and the risks of ischemic stroke, heart failure, mortality, and adverse events when performed early (<3 Months): a nationwide cohort study of newly diagnosed patients with atrial fibrillation","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemostasis"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00392-021-01914-y","article-title":"Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry","volume":"111","author":"Proietti","year":"2022","journal-title":"Clin Res Cardiol: official journal of the German Cardiac Society"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100797_bib86","article-title":"Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation","volume":"11","author":"Dickow","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"23","key":"10.1016\/j.lanepe.2023.100797_bib87","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1136\/heartjnl-2022-321196","article-title":"Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank","volume":"108","author":"Kany","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.lanepe.2023.100797_bib88","doi-asserted-by":"crossref","first-page":"n991","DOI":"10.1136\/bmj.n991","article-title":"Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study","volume":"373","author":"Kim","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100797_bib89","article-title":"Risks and benefits of early rhythm control in patients with acute strokes and atrial fibrillation: a multicenter, prospective, randomized study (the RAFAS trial)","volume":"11","author":"Park","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.hrthm.2020.12.025","article-title":"The role of timing in treatment of atrial fibrillation: an AFFIRM substudy","volume":"18","author":"Yang","year":"2021","journal-title":"Heart Rhythm"},{"issue":"24","key":"10.1016\/j.lanepe.2023.100797_bib91","article-title":"Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation","volume":"10","author":"Kim","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100797_bib92","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/CIRCULATIONAHA.122.060274","article-title":"Early rhythm control in patients with atrial fibrillation and high comorbidity burden","volume":"146","author":"Rillig","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.lanepe.2023.100797_bib93","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.122.011585","article-title":"Outcomes of early rhythm control therapy in patients with atrial fibrillation and a high comorbidity burden in large real-world cohorts","volume":"16","author":"Dickow","year":"2023","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib94","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/europace\/euab200","article-title":"Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial","volume":"24","author":"Metzner","year":"2022","journal-title":"Europace"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib95","article-title":"Comprehensive management with the ABC (atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial","volume":"9","author":"Proietti","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib96","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41569-022-00820-8","article-title":"Epidemiology and modifiable risk factors for atrial fibrillation","volume":"20","author":"Elliott","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100797_bib97","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jacc.2018.05.076","article-title":"Ideal blood pressure in patients with atrial fibrillation","volume":"72","author":"Kim","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.lanepe.2023.100797_bib98","article-title":"Impact of achieving blood pressure targets and high time in therapeutic range on clinical outcomes in patients with atrial fibrillation adherent to the atrial fibrillation better care pathway: a report from the COOL-AF registry","volume":"12","author":"Krittayaphong","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91923-8","article-title":"Associations of hypertension burden on subsequent dementia: a population-based cohort study","volume":"11","author":"Jung","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.116.023163","article-title":"Modifiable risk factors and atrial fibrillation","volume":"136","author":"Lau","year":"2017","journal-title":"Circulation"},{"issue":"32","key":"10.1016\/j.lanepe.2023.100797_bib101","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/eurheartj\/ehx739","article-title":"Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial","volume":"39","author":"Rienstra","year":"2018","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.lanepe.2023.100797_bib102","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/jama.2013.280521","article-title":"Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial","volume":"310","author":"Abed","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib103","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/europace\/euab122","article-title":"Supervised Obesity Reduction Trial for AF ablation patients: results from the SORT-AF trial","volume":"23","author":"Gessler","year":"2021","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib104","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1817591","article-title":"Alcohol abstinence in drinkers with atrial fibrillation","volume":"382","author":"Voskoboinik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.lanepe.2023.100797_bib105","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCULATIONAHA.116.026230","article-title":"Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [substrate modification with aggressive blood pressure control])","volume":"135","author":"Parkash","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib106","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.115.018220","article-title":"Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial","volume":"133","author":"Malmo","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lanepe.2023.100797_bib107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijcard.2018.11.100","article-title":"The impact of continuous positive airway pressure treatment on the recurrence of atrial fibrillation post cardioversion: a randomized controlled trial","volume":"278","author":"Caples","year":"2019","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib108","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.202011-4133OC","article-title":"Effect of continuous positive airway pressure on arrhythmia in atrial fibrillation and sleep apnea: a randomized controlled trial","volume":"204","author":"Traaen","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.lanepe.2023.100797_bib109","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.hrthm.2022.06.016","article-title":"Effect of continuous positive airway pressure therapy on recurrence of atrial fibrillation after pulmonary vein isolation in patients with obstructive sleep apnea: a randomized controlled trial","volume":"19","author":"Hunt","year":"2022","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib110","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/europace\/euab270","article-title":"Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial","volume":"24","author":"Nguyen","year":"2022","journal-title":"Europace"},{"issue":"15","key":"10.1016\/j.lanepe.2023.100797_bib111","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/eurheartj\/ehab672","article-title":"ESC and EHRA lead a path towards integrated care for multimorbid atrial fibrillation patients: the Horizon 2020 EHRA-PATHS project","volume":"43","author":"Heidbuchel","year":"2022","journal-title":"Eur Heart J"},{"issue":"37","key":"10.1016\/j.lanepe.2023.100797_bib112","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great Debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week","volume":"43","author":"De Caterina","year":"2022","journal-title":"Eur Heart J"},{"issue":"9872","key":"10.1016\/j.lanepe.2023.100797_bib113","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.lanepe.2023.100797_bib114","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.lanepe.2023.100797_bib115","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.lanepe.2023.100797_bib116","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10206","key":"10.1016\/j.lanepe.2023.100797_bib117","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanepe.2023.100797_bib118","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"issue":"46","key":"10.1016\/j.lanepe.2023.100797_bib119","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lanepe.2023.100797_bib120","article-title":"Antiplatelet agents and oral anticoagulant use in patients with atrial fibrillation and carotid artery disease after first-time ischaemic stroke","author":"Harrison","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9586","key":"10.1016\/j.lanepe.2023.100797_bib121","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.lanepe.2023.100797_bib122","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.lanepe.2023.100797_bib123","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/jgs.17884","article-title":"Oral anticoagulants and outcomes in adults >\/=80 years with atrial fibrillation: a global federated health network analysis","volume":"70","author":"Harrison","year":"2022","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib124","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.hrthm.2021.02.018","article-title":"Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation","volume":"18","author":"Chao","year":"2021","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.lanepe.2023.100797_bib125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/europace\/euz344","article-title":"Challenges in stroke prevention among very elderly patients with atrial fibrillation: discerning facts from prejudices","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib126","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/a-2021-8910","article-title":"Direct oral anticoagulants in the very elderly","volume":"123","author":"Eikelboom","year":"2023","journal-title":"Thromb Haemostasis"},{"issue":"13","key":"10.1016\/j.lanepe.2023.100797_bib127","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib128","first-page":"1389","article-title":"2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation","volume":"37","author":"Chao","year":"2021","journal-title":"J\u00a0Arrhythm"},{"issue":"18","key":"10.1016\/j.lanepe.2023.100797_bib129","article-title":"Atrial fibrillation and ischemic stroke despite oral anticoagulation","volume":"12","author":"Galea","year":"2023","journal-title":"J\u00a0Clin Med"},{"issue":"20","key":"10.1016\/j.lanepe.2023.100797_bib130","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/eurheartj\/ehad200","article-title":"Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation","volume":"44","author":"Benz","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.lanepe.2023.100797_bib131","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ana.25700","article-title":"Ischemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation","volume":"87","author":"Seiffge","year":"2020","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib132","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1212\/WNL.0000000000207422","article-title":"Association of alternative anticoagulation strategies and outcomes in patients with ischemic stroke while taking a direct oral anticoagulant","volume":"101","author":"Ip","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib133","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1161\/STROKEAHA.122.041197","article-title":"Recurrent ischemic stroke and cardiovascular outcomes in patients with atrial fibrillation with ischemic stroke despite direct oral anticoagulants","volume":"54","author":"Hsieh","year":"2023","journal-title":"Stroke"},{"issue":"16","key":"10.1016\/j.lanepe.2023.100797_bib134","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","article-title":"Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage","volume":"133","author":"Chao","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.lanepe.2023.100797_bib135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S1474-4422(21)00264-7","article-title":"Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial","volume":"20","author":"So","year":"2021","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.lanepe.2023.100797_bib136","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S1474-4422(21)00298-2","article-title":"Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial","volume":"20","author":"Schreuder","year":"2021","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.lanepe.2023.100797_bib137","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.lanepe.2023.100797_bib138","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.lanepe.2023.100797_bib139","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A\u00a0randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"issue":"10333","key":"10.1016\/j.lanepe.2023.100797_bib140","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776223002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:57:56Z","timestamp":1763009876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776223002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":140,"alternative-id":["S2666776223002168"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100797","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrial fibrillation: stroke prevention","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100833","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100786","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100785","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100784","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2023.100801","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100797"}}